×
About 170,140 results

Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J...
https://doi.org/10.1016/S0140-6736(17)30565-2
Lancet (London, England); Hida T, Nokihara H et. al.

May 15th, 2017 - Alectinib, a potent, highly selective, CNS-active inhibitor of anaplastic lymphoma kinase (ALK), showed promising efficacy and tolerability in the single-arm phase 1/2 AF-001JP trial in Japanese patients with ALK-positive non-small-cell lung cancer. Given those promising results, we did a phase 3 trial to directly compare the efficacy and safety of alectinib and crizotinib. J-ALEX was a randomi...

New Delhi metallo-β-lactamase-producing carbapenem-resistant Escherichia coli associate...
https://doi.org/10.1001/jama.2014.12720
JAMA Epstein L, Hunter JC et. al.

Oct 7th, 2014 - Carbapenem-resistant Enterobacteriaceae (CRE) producing the New Delhi metallo-β-lactamase (NDM) are rare in the United States, but have the potential to add to the increasing CRE burden. Previous NDM-producing CRE clusters have been attributed to person-to-person transmission in health care facilities. To identify a source for, and interrupt transmission of, NDM-producing CRE in a northeastern ...

Gefitinib Plus Chemotherapy Versus Chemotherapy in Epidermal Growth Factor Receptor Mut...
https://doi.org/10.1200/JCO.2017.73.9250
Journal of Clinical Oncology : Official Journal of the Am... Mok TSK, Kim SW et. al.

Oct 2nd, 2017 - Purpose The Iressa Mutation-Positive Multicentre Treatment Beyond ProgRESsion Study (IMPRESS) compared the continuation of gefitinib plus chemotherapy with placebo plus chemotherapy in patients with epidermal growth factor receptor ( EGFR) mutation-positive advanced non-small-cell lung cancer with progression (Response Evaluation Criteria in Solid Tumors 1.1) after first-line gefitinib. Primary...

Antimicrobials increase travelers' risk of colonization by extended-spectrum betalactam...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4345818
Clinical Infectious Diseases : an Official Publication Of... Kantele A, Lääveri T et. al.

Jan 23rd, 2015 - More than 300 million travelers visit regions with poor hygiene annually. A significant percentage of them become colonized by resistant intestinal bacteria such as extended-spectrum beta-lactamase-producing Enterobacteriaceae (ESBL-PE) and may transmit the strains to others and to medical care settings when they return home. Despite the threats to global healthcare caused by an upsurge in anti...

Telomerase Inhibitor Imetelstat in Patients with Essential Thrombocythemia.
https://doi.org/10.1056/NEJMoa1503479
The New England Journal of Medicine; Baerlocher GM, Oppliger Leibundgut E et. al.

Sep 3rd, 2015 - Imetelstat, a 13-mer oligonucleotide that is covalently modified with lipid extensions, competitively inhibits telomerase enzymatic activity. It has been shown to inhibit megakaryocytic proliferation in vitro in cells obtained from patients with essential thrombocythemia. In this phase 2 study, we investigated whether imetelstat could elicit hematologic and molecular responses in patients with ...

Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients Wit...
https://doi.org/10.1053/j.gastro.2015.05.010
Gastroenterology Charlton M, Everson GT et. al.

May 19th, 2015 - There are no effective and safe treatments for chronic hepatitis C virus (HCV) infection of patients who have advanced liver disease. In this phase 2, open-label study, we assessed treatment with the NS5A inhibitor ledipasvir, the nucleotide polymerase inhibitor sofosbuvir, and ribavirin in patients infected with HCV genotypes 1 or 4. Cohort A enrolled patients with cirrhosis and moderate or se...

High-fidelity CRISPR-Cas9 nucleases with no detectable genome-wide off-target effects.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4851738
Nature Kleinstiver BP, Pattanayak V et. al.

Jan 6th, 2016 - CRISPR-Cas9 nucleases are widely used for genome editing but can induce unwanted off-target mutations. Existing strategies for reducing genome-wide off-target effects of the widely used Streptococcus pyogenes Cas9 (SpCas9) are imperfect, possessing only partial or unproven efficacies and other limitations that constrain their use. Here we describe SpCas9-HF1, a high-fidelity variant harbouring ...

Import and spread of extended-spectrum β-lactamase-producing Enterobacteriaceae by inte...
https://doi.org/10.1016/S1473-3099(16)30319-X
The Lancet. Infectious Diseases; Arcilla MS, van Hattem JM et. al.

Oct 18th, 2016 - International travel contributes to the dissemination of antimicrobial resistance. We investigated the acquisition of extended-spectrum β-lactamase-producing Enterobacteriaceae (ESBL-E) during international travel, with a focus on predictive factors for acquisition, duration of colonisation, and probability of onward transmission. Within the prospective, multicentre COMBAT study, 2001 Dutch tra...

Permanent alteration of PCSK9 with in vivo CRISPR-Cas9 genome editing.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4134749
Circulation Research; Ding Q, Strong A et. al.

Jun 11th, 2014 - Individuals with naturally occurring loss-of-function proprotein convertase subtilisin/kexin type 9 (PCSK9) mutations experience reduced low-density lipoprotein cholesterol levels and protection against cardiovascular disease. The goal of this study was to assess whether genome editing using a clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated system can effici...

Glutenase ALV003 attenuates gluten-induced mucosal injury in patients with celiac disease.
https://doi.org/10.1053/j.gastro.2014.02.031
Gastroenterology Lähdeaho ML, Kaukinen K et. al.

Mar 3rd, 2014 - Gluten ingestion leads to small intestinal mucosal injury in patients with celiac disease, necessitating strict life-long exclusion of dietary gluten. Despite adherence to a gluten-free diet, many patients remain symptomatic and still have small intestinal inflammation. In this case, nondietary therapies are needed. We investigated the ability of ALV003, a mixture of 2 recombinant gluten-specif...

The sonic hedgehog factor GLI1 imparts drug resistance through inducible glucuronidation.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4138053
Nature Zahreddine HA, Culjkovic-Kraljacic B et. al.

May 29th, 2014 - Drug resistance is a major hurdle in oncology. Responses of acute myeloid leukaemia (AML) patients to cytarabine (Ara-C)-based therapies are often short lived with a median overall survival of months. Therapies are under development to improve outcomes and include targeting the eukaryotic translation initiation factor (eIF4E) with its inhibitor ribavirin. In a Phase II clinical trial in poor pr...

Trastuzumab emtansine in human epidermal growth factor receptor 2-positive metastatic b...
https://doi.org/10.1200/JCO.2013.54.4999
Journal of Clinical Oncology : Official Journal of the Am... Diéras V, Harbeck N et. al.

Jul 15th, 2014 - The antibody-drug conjugate trastuzumab emtansine (T-DM1) combines the cytotoxic activity of DM1 with the human epidermal growth factor receptor 2 (HER2) -targeted, antitumor properties of trastuzumab. T-DM1 has shown activity in phase I and II single-arm studies in patients with pretreated HER2-positive metastatic breast cancer (MBC) and has demonstrated superior efficacy and improved tolerabi...

Long-term survival of sorafenib-treated FLT3-ITD-positive acute myeloid leukaemia patie...
https://doi.org/10.1016/j.ejca.2017.09.016
European Journal of Cancer (Oxford, England : 1990); Metzelder SK, Schroeder T et. al.

Oct 21st, 2017 - Fms-like tyrosine kinase 3 internal tandem duplication (FLT3-ITD)-positive acute myeloid leukaemia (AML) relapsing after allogeneic stem cell transplantation (allo-SCT) has a dismal prognosis with limited therapeutic options. FLT3-ITD kinase inhibition is a reasonable but palliative experimental treatment alternative in this situation. Information on long-term outcome is not available. We perfo...

The Impact of Local Intervention Combined with Targeted Therapy on Metastatic Renal Cel...
https://doi.org/10.21873/anticanres.12861
Anticancer Research; Li JR, Ou YC et. al.

Sep 8th, 2018 - We performed a retrospective survey on our metastatic renal cell carcinoma (MRCC) patients who had received targeted therapies, and afterwards evaluated the clinical impacts of local interventions on the patient outcomes. Between 2006 and 2016, 124 patients with MRCC who had received at least one line of tyrosine kinase inhibitors or mammalian target of rapamycin were included in the study. Sev...

Role of Cytotoxic Tumor-Infiltrating Lymphocytes in Predicting Outcomes in Metastatic H...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5824197
JAMA Oncology; Liu S, Chen B et. al.

Jul 27th, 2017 - Accumulating evidence indicates that tumor-infiltrating lymphocytes (TILs) are associated with clinical outcomes and may predict the efficacy of chemotherapy and human epidermal growth factor receptor 2 (HER2, encoded by the gene ERBB2)-targeted therapy in patients with HER2-positive breast cancer. To investigate the role of TILs, particularly cytotoxic CD8+ T cells, in the prediction of outcom...

The prognostic impact of cancer stem-like cell biomarker aldehyde dehydrogenase-1 (ALDH...
https://doi.org/10.1016/j.ygyno.2018.05.006
Gynecologic Oncology; Ruscito I, Darb-Esfahani S et. al.

May 13th, 2018 - To investigate the association of cancer stem cell biomarker aldehyde dehydrogenase-1 (ALDH1) with ovarian cancer patients' prognosis and clinico-pathological characteristics. The electronic searches were performed in January 2018 through the databases PubMed, MEDLINE and Scopus by searching the terms: "ovarian cancer" AND "immunohistochemistry" AND ["aldehyde dehydrogenase-1" OR "ALDH1" OR "ca...

The Accuracy of Serum Matrix Metalloproteinase-9 for Predicting Hemorrhagic Transformat...
https://doi.org/10.1016/j.jstrokecerebrovasdis.2018.01.023
Journal of Stroke and Cerebrovascular Diseases : the Offi... Wang L, Wei C et. al.

Mar 30th, 2018 - Hemorrhagic transformation is a serious complication of acute ischemic stroke, which may cause detrimental outcomes and the delayed use of anticoagulation therapy. Early predicting and identifying the patients at high risk of hemorrhagic transformation before clinical deterioration occurrence become a research priority. To study the value of plasma matrix metalloproteinase-9 predicting hemorrha...

Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic s...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4447192
Lancet (London, England); Neuschwander-Tetri BA, Loomba R et. al.

Dec 3rd, 2014 - The bile acid derivative 6-ethylchenodeoxycholic acid (obeticholic acid) is a potent activator of the farnesoid X nuclear receptor that reduces liver fat and fibrosis in animal models of fatty liver disease. We assessed the efficacy of obeticholic acid in adult patients with non-alcoholic steatohepatitis. We did a multicentre, double-blind, placebo-controlled, parallel group, randomised clinica...

Phosphodiesterase 9A controls nitric-oxide-independent cGMP and hypertrophic heart dise...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4376609
Nature Lee DI, Zhu G et. al.

Mar 24th, 2015 - Cyclic guanosine monophosphate (cGMP) is a second messenger molecule that transduces nitric-oxide- and natriuretic-peptide-coupled signalling, stimulating phosphorylation changes by protein kinase G. Enhancing cGMP synthesis or blocking its degradation by phosphodiesterase type 5A (PDE5A) protects against cardiovascular disease. However, cGMP stimulation alone is limited by counter-adaptions in...

In vivo genome editing using Staphylococcus aureus Cas9.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4393360
Nature Ran FA, Cong L et. al.

Apr 1st, 2015 - The RNA-guided endonuclease Cas9 has emerged as a versatile genome-editing platform. However, the size of the commonly used Cas9 from Streptococcus pyogenes (SpCas9) limits its utility for basic research and therapeutic applications that use the highly versatile adeno-associated virus (AAV) delivery vehicle. Here, we characterize six smaller Cas9 orthologues and show that Cas9 from Staphylococc...